Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...

A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes key challenges by incorporating alternative ... resulting in enhanced performance of a COVID-19 vaccine with ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes key challenges by incorporating alternative ... resulting in enhanced performance of a COVID-19 vaccine with ...

Arcturus Therapeutics’ H5N1 pandemic influenza vaccine candidate, ARCT-2304, is a self-amplifying mRNA vaccine candidate, whose Phase I clinical trial is funded by BARDA. The randomised, ...